| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C16H19IN2O5.Tc |
| Molecular Weight | 991.3801 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[99Tc+4].CCC1=C(NC(=O)CN(CC([O-])=O)CC([O-])=O)C(CC)=C(I)C=C1.CCC2=C(NC(=O)CN(CC([O-])=O)CC([O-])=O)C(CC)=C(I)C=C2
InChI
InChIKey=KKRISYPFLIKFPU-FCHARDOESA-J
InChI=1S/2C16H21IN2O5.Tc/c2*1-3-10-5-6-12(17)11(4-2)16(10)18-13(20)7-19(8-14(21)22)9-15(23)24;/h2*5-6H,3-4,7-9H2,1-2H3,(H,18,20)(H,21,22)(H,23,24);/q;;+4/p-4/i;;1+1
Molybdenum-99 (99Mo, half-life = 66 h) is a parent radionuclide of a diagnostic nuclear isotope. It decays in technetium-99 m (half-life = 6 h), which is used in over 30 million procedures per year around the world. Between 95 and 98 percent of Mo-99 is currently being produced using highly enriched uranium (HEU) targets. Other medical isotopes such as iodine-131 (I-131) and xenon-133 (Xe-133) are by-products of the Mo-99 production process and will be sufficiently available if Mo-99 is available.
Approval Year
PubMed
Patents
ACTIVE MOIETY
ACTIVE MOIETY
